MicroShunt与小梁切除术治疗原发性开角型青光眼:两年随机多中心研究的一年结果
这项前瞻性随机多中心非劣效性研究比较了MicroShunt与小梁切除术治疗原发性开角型青光眼的效果与安全性。一年结果显示,MicroShunt组手术成功概率低于小梁切除术组(53.9% vs 72.7%),小梁切除术组眼压降幅更大且用药更少,但小梁切除术组术后干预和短暂性低眼压发生率更高。
要点
- MicroShunt组一年手术成功概率为53.9%,低于小梁切除术组的72.7%。
- 小梁切除术组眼压降幅更大(-45.4% vs -29.1%),且用药更少。
- 小梁切除术组术后干预(67.4% vs 40.8%)和短暂性低眼压(49.6% vs 28.9%)更常见。
核心结论
- MicroShunt手术成功概率低于小梁切除术,但小梁切除术组眼压更低且用药更少。
- 两组均观察到眼压和青光眼用药减少,视力威胁性并发症少见。
研究设计与样本
- 为期2年的前瞻性、随机、多中心、非劣效性研究的一年结果,在美国和欧洲开展(NCT01881425)。
- 纳入40-85岁、眼压≥15且≤40 mmHg、最大耐受药物治疗下控制不佳的轻至重度原发性开角型青光眼患者。
- 患者按3:1随机接受单独MicroShunt植入或小梁切除术,均辅助使用丝裂霉素C(0.2 mg/ml,2分钟)。
主要发现
- MicroShunt组395例,小梁切除术组132例随机,平均Humphrey视野平均偏差-12.34 dB。
- 一年时手术成功概率MicroShunt组53.9%,小梁切除术组72.7%(P < 0.01)。
- MicroShunt组平均眼压从基线21.1 ± 4.9 mmHg降至14.3 ± 4.3 mmHg(-29.1%;P < 0.01),平均用药0.6 ± 1.1种(基线3.1 ± 1.0;P < 0.01)。
- 小梁切除术组平均眼压从21.1 ± 5.0 mmHg降至11.1 ± 4.3 mmHg(-45.4%;P < 0.01),平均用药0.3 ± 0.9种(基线3.0 ± 0.9;P < 0.01)。
- 术后干预(包括激光缝线松解)报告率MicroShunt组40.8%,小梁切除术组67.4%(P < 0.01);短暂性低眼压发生率小梁切除术组49.6%,MicroShunt组28.9%(P < 0.01)。
关键数值与推荐
- 主要有效性终点为一年时平均日间眼压较基线(无药物洗脱)降低≥20%且青光眼用药数量不增加的手术成功。
- 视力威胁性并发症报告率MicroShunt组1.0%,小梁切除术组0.8%。
临床怎么用
- MicroShunt可作为需手术的青光眼患者的一种选择,但需告知其手术成功概率低于小梁切除术。
- 小梁切除术降压幅度更大且术后用药更少,但术后干预和短暂性低眼压更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the effectiveness and safety of the MicroShunt versus trabeculectomy in patients with primary open-angle glaucoma (POAG). DESIGN: One-year results from a 2-year, prospective, randomized, multicenter, noninferiority study (NCT01881425) conducted in the United States and Europe. PARTICIPANTS: Eligible patients were aged 40-85 years with intraocular pressure (IOP) ≥15 and ≤40 mmHg and mild-to-severe POAG inadequately controlled on maximum tolerated medical therapy. METHODS: Patients were randomized 3:1 to undergo stand-alone MicroShunt implantation or trabeculectomy, both performed with adjunctive mitomycin C (0.2 mg/ml for 2 minutes). MAIN OUTCOME MEASURES: The primary effectiveness end point was surgical success, defined as ≥20% reduction in mean diurnal IOP from baseline (no medication washout) at year 1 without increasing the number of glaucoma medications. Secondary effectiveness end points at year 1 were the mean IOP change from baseline and requirement for postoperative intervention. Additional end points included glaucoma medication use and adverse events. RESULTS: Overall, 395 (MicroShunt) and 132 (trabeculectomy) patients were randomized (mean Humphrey visual field mean deviation, -12.34 decibels [dB]). At year 1, probability of success was lower in the MicroShunt group compared with the trabeculectomy group (53.9% vs. 72.7%, respectively; P < 0.01). In the MicroShunt group, mean IOP ± standard deviation decreased from 21.1 ± 4.9 mmHg at baseline to 14.3 ± 4.3 mmHg (-29.1%; P < 0.01) at year 1, with a mean of 0.6 ± 1.1 glaucoma medications (baseline 3.1 ± 1.0; P < 0.01). In the trabeculectomy group, mean IOP decreased from 21.1 ± 5.0 mmHg to 11.1 ± 4.3 mmHg (-45.4%; P < 0.01), with a mean of 0.3 ± 0.9 glaucoma medications (baseline 3.0 ± 0.9; P < 0.01). Postoperative interventions, including laser suture lysis, were reported in 40.8% (MicroShunt) versus 67.4% (trabeculectomy) of patients (P < 0.01). Reported incidence of transient hypotony was higher in the trabeculectomy group versus the MicroShunt group (49.6% vs. 28.9%; P < 0.01). Vision-threatening complications were uncommon and reported in 1.0% of MicroShunt versus 0.8% of trabeculectomy patients. CONCLUSIONS: Probability of success was lower with MicroShunt compared with trabeculectomy. Although reductions in IOP and glaucoma medications over 1 year were observed in both groups, the trabeculectomy group had a lower mean IOP on fewer medications.
引用
- Baker ND, Barnebey HS, Moster MR, et al. Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: One-Year Results from a 2-Year Randomized, Multicenter Study. Ophthalmology. 2021. PMID: 34051211. doi:10.1016/j.ophtha.2021.05.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。